(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

ANTICORPOS TENDO ESPECIFICIDADE PARA BTN2 E USOS DOS MESMOS

Em ExigênciaInvention PatentPCT · EP2020057794

Application data

Number

112021018611

Type

Invention Patent

Filing

03/20/2020

Publication

11/23/2021

PCT

EP2020057794

Progress at the INPI

Technical opinion to answer
  1. Filing03/20/20
  2. Publication11/23/21
  3. Examination
  4. Allowance
  5. Grant
  6. In force

The INPI issued a technical opinion on patentability. The applicant must respond for examination to continue.

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 04/22/2026. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS

FR

IMCHECK THERAPEUTICS SAS

FR

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

FR

INSTITUT JEAN PAOLI & IRENE CALMETTES

FR

U. D. (pessoa física)

FR

See this company's full portfolio

Inventors

C. C. (pessoa física)

FR

C. P. (pessoa física)

FR

D. O. (pessoa física)

FR

E. F. (pessoa física)

FR

K. L. (pessoa física)

FR

Technical data

IPC Classification

Priority claims

EP

19219691.3 · 12/24/2019

EP

19305345.1 · 03/20/2019

Abstract

ANTICORPOS TENDO ESPECIFICIDADE PARA BTN2 E USOS DOS MESMOS.A presente invenção se refere a anticorpos tendo especificidade para BTN2A e usos dos mesmos, em particular para o tratamento de câncer.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Parecer de pré-exame

#6.23

04/22/2026

RPI 2885

Notificação de entrada na fase nacional - PCT

#1.3

11/23/2021

RPI 2655

Alteração de dados cadastrais

#1.1

09/28/2021

RPI 2647

Related

From the same holder

Same category

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.